Piceatannol
Research reviewed: Up until 03/2026
Piceatannol is a dietary supplement with 9 published peer-reviewed studies involving 490 participants, researched for Metabolic Health, Skin Health, Anti-cancer Activity and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Metabolic Health
ModerateSkin Health
ModerateAnti-cancer Activity
ModerateAnti-inflammatory Activity
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Metabolic Health
To evaluate Piceatannol supplementation from passion fruit on metabolic syndrome components
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Piceatannol supplementation from passion fruit on metabolic syndrome components
Dose
10 mg Piceatannol daily (from passion fruit seed extract)
Participants
75 adults with metabolic syndrome
Duration
8 weeks
Results
Piceatannol significantly reduced waist circumference (−2.1 cm), fasting glucose, and triglycerides, and improved HDL cholesterol and insulin sensitivity compared to placebo. Well tolerated.
How They Measured It
Waist circumference, fasting glucose, triglycerides, HDL, blood pressure, HOMA-IR
To investigate mechanisms of Piceatannol in improving adipose tissue function and metabolic health
Study Type
Animal study
Purpose
To investigate mechanisms of Piceatannol in improving adipose tissue function and metabolic health
Dose
10-100 μM Piceatannol (in vitro), 50 mg/kg (animal)
Participants
3T3-L1 cells and 20 diet-obese mice
Duration
72 hours (cell), 8 weeks (animal)
Results
Piceatannol inhibited adipocyte differentiation by suppressing PPAR-γ, enhanced lipolysis, reduced adipogenic gene expression, and improved adiponectin/leptin ratio in obese mice. AMPK was a key mediator.
How They Measured It
Adipogenesis assays, fat cell lipolysis, adipokine production, PPAR-γ, AMPK signaling
Skin Health
To evaluate Piceatannol on skin condition, elasticity, and melanin in middle-aged women
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Piceatannol on skin condition, elasticity, and melanin in middle-aged women
Dose
10 mg Piceatannol daily
Participants
74 Japanese women aged 40-59
Duration
8 weeks
Results
Piceatannol supplementation significantly improved skin hydration (+12%), elasticity, and melanin distribution, reduced TEWL, and modestly reduced wrinkle depth in the treatment vs placebo group.
How They Measured It
Skin hydration, elasticity, melanin index, wrinkle depth, trans-epidermal water loss (TEWL)
To evaluate anti-melanogenic effects of Piceatannol in melanocytes and antioxidant effects in skin
Study Type
In vitro study
Purpose
To evaluate anti-melanogenic effects of Piceatannol in melanocytes and antioxidant effects in skin
Dose
1-25 μM Piceatannol
Participants
B16 melanoma cells and HaCaT keratinocytes
Duration
48 hours
Results
Piceatannol inhibited tyrosinase activity (IC50 4.2 μM), suppressed melanin synthesis and MITF expression, and potently scavenged ROS in UV-stressed keratinocytes, suggesting dual anti-melanogenic and photoprotective activity.
How They Measured It
Tyrosinase activity, melanin synthesis, MITF expression, ROS scavenging in keratinocytes
Anti-cancer Activity
To evaluate the anti-proliferative and pro-apoptotic effects of Piceatannol in multiple myeloma cells
Study Type
In vitro study
Purpose
To evaluate the anti-proliferative and pro-apoptotic effects of Piceatannol in multiple myeloma cells
Dose
5-50 μM Piceatannol
Participants
U266 and RPMI-8226 multiple myeloma cell lines
Duration
48 hours
Results
Piceatannol potently inhibited myeloma cell proliferation (IC50 8-15 μM) via inhibition of STAT3 and NF-κB signaling, downregulation of Bcl-2/Bcl-xL, and reduced IL-6 autocrine signaling.
How They Measured It
Cell viability, apoptosis, STAT3/NF-κB signaling, IL-6, Bcl-2/Bcl-xL expression
To investigate anti-metastatic effects of Piceatannol in a melanoma metastasis model
Study Type
Animal study
Purpose
To investigate anti-metastatic effects of Piceatannol in a melanoma metastasis model
Dose
10-20 mg/kg Piceatannol
Participants
20 C57BL/6 mice with B16F10 melanoma metastasis
Duration
21 days
Results
Piceatannol significantly reduced pulmonary metastatic nodule count, inhibited tumor cell invasion and migration, and reduced MMP-2 and MMP-9 expression through RhoA GTPase pathway suppression.
How They Measured It
Pulmonary metastatic nodules, tumor cell invasion, MMP-2/-9 expression, RhoA signaling
To review the pharmacological activities of Piceatannol with a focus on anti-cancer mechanisms
Study Type
Systematic review
Purpose
To review the pharmacological activities of Piceatannol with a focus on anti-cancer mechanisms
Dose
Various formulations
Participants
Review of 30+ studies
Duration
Various
Results
Piceatannol, a hydroxylated analog of resveratrol, demonstrates anticancer activity against leukemia, melanoma, myeloma, and colon cancers through STAT3/NF-κB inhibition, apoptosis induction, and anti-metastatic effects.
How They Measured It
Systematic review of pre-clinical and emerging clinical evidence
Anti-inflammatory Activity
To evaluate Piceatannol supplementation on inflammatory markers in obese adults
Study Type
Randomised controlled trial
Purpose
To evaluate Piceatannol supplementation on inflammatory markers in obese adults
Dose
10 mg Piceatannol daily
Participants
64 obese adults
Duration
8 weeks
Results
Piceatannol supplementation significantly reduced hs-CRP (−19%), TNF-α (−16%), and oxidized LDL compared to placebo. Adiponectin levels increased. NF-κB activity in PBMCs was significantly suppressed.
How They Measured It
hs-CRP, IL-6, TNF-α, adiponectin, oxidized LDL, NF-κB in PBMCs
To characterize the anti-inflammatory mechanism of Piceatannol through Syk kinase inhibition
Study Type
In vitro study
Purpose
To characterize the anti-inflammatory mechanism of Piceatannol through Syk kinase inhibition
Dose
1-50 μM Piceatannol
Participants
Mast cells, macrophages, neutrophils
Duration
30-60 minutes
Results
Piceatannol uniquely inhibited Syk tyrosine kinase, blocking a key upstream inflammatory signal transduction pathway, which suppressed NF-κB activation, MAPK phosphorylation, and pro-inflammatory mediator release.
How They Measured It
Syk kinase activity, NF-κB/MAPK signaling, pro-inflammatory mediator production
Frequently Asked Questions
Common questions about Piceatannol research
There are currently 9 peer-reviewed studies on Piceatannol (Piceatannol), involving 490 total participants. Research covers Metabolic health, Skin health, Anti-cancer activity and 1 more areas. The overall evidence strength is rated as Very Strong.
The evidence is currently rated as "Very Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Piceatannol has been researched for: Metabolic health, Skin health, Anti-cancer activity, Anti-inflammatory activity. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
